Surname: UMAR
Other names: Abdullahi Bello
Sex: Male
Date of Birth: 31st December, 1988
Place of Birth: Malumfashi
Home Town: Malumfashi
Local Government Area: Malumfashi
State of Origin: Katsina
Nationality: Nigerian
Marital Status: Married
Contact Address: Department of Chemistry, Faculty of Physical Sciences, Ahmad Bello
University, Zaria, P.M.B.1045 Kaduna State, Nigeria.
Email Address: abdallahbum@yahoo.com, buabdullahi@abu.edu.ng
EDUCATION
First School Leaving Certificate 2001
Senior School Certificate (O/L) 2007
Bachelor of Science, 2.1 (Chemistry) BUK 2012
Master of Science (Physical Chemistry) ABU Zaria 2018
Doctor of Philosophy (Physical and Theoretical Chemistry) ABU Zaria 2021
WORK EXPERIENCE
Chemistry Teacher Government Secondary School, Minna (NYSC) 2012-2013
Laboratory Demonstrator Ahmad Bello University, Zaria 2014-2015
Master Grade II School of Pre-Degree and Remedial studies UMYU,Katsina 2016-2017
Part-Time Lecturer Ahmad Bello University, Zaria 2016-2017
Graduate Assistant Ahmad Bello University, Zaria 2017-2018
Assistant Lecturer Ahmad Bello University, Zaria 2018-2021
Lecturer II Ahmad Bello University, Zaria 2021-Date
PUBLICATIONS
1. Umar, B. A., and Uzairu, A. (2019). In-silico approach to understand the inhibition of corrosion by some potent triazole derivatives of pyrimidine for steel. SN Applied Sciences, 1(11), 1413.
2. Abdullahi, M., Shallangwa, G. A., Ibrahim, M. T., Bello, A. U., Arthur, D. E., Uzairu, A., and Mamzaa, P.(2019). QSAR studies on some C14-urea tetrandrine compounds as potent anti-cancer agents against Leukemia cell line (K562). Journal of the Turkish Chemical Society Section A: Chemistry:5(3): 1387-1398.
3. Abdulfatai, U., Uba, S., Umar, B. A., and Ibrahim, M. T. (2019). Molecular design and docking analysis of the inhibitory activities of some α_substituted acetamido-N-benzylacetamide as anticonvulsant agents. SN Applied Sciences, 1(5), 499.
4. Umar, B. A., Uzairu, A., Shallangwa, G. A., and Uba, S. (2019). Rational drug design of potent v600e-braf kinase inhibitors through molecular docking simulation. The Journal of Engineering and Exact Sciences, 5(5), 0469-0481.
5. Ibrahim M. T., A. Uzairu A., Umar B. A., Sadiq B. A. and Isyaku Y. (2020). Molecular modelling, docking and pharmacokinetic studies of n-arylidenequinoline-3-carbohydrazides analogs as novel β-glucuronidase inhibitors. The Journal of Mexican Chemical Society 64(1).
6. Isyaku, Y., Uzairu, A., Uba, S., Ibrahim, M. T., Umar, A. B. (2020). QSAR, molecular docking, and design of novel 4-(N, N-diarylmethyl amines) Furan-2 (5 H)-one derivatives as insecticides against Aphis craccivora Bulletin of the National Research Centre 44:1-11.
7. Abdullahi, M., Uzairu, A., Shallangwa, G. A., Arthur, D. E., Umar, B. A., Ibrahim, M. T. (2020). Virtual molecular docking study of some novel carboxamide series as new anti-tubercular agents European Journal of Chemistry 11:30-36.
8. Ibrahim, M. T., Tahir, S. M., Umar, A. B., and Abdulfatai, U. (2020). Theoretical investigation and design of some indole derivatives as potent β-glucuronidase inhibitors. Bulletin of the National Research Centre, 44(1), 1-11.
9. Bello, A. U., Uzairu, A., and Shallangwa, G. A. (2020). Evaluation of Anticorrosion Properties of 1, 2, 4-triazole Derivatives on Steel in Acidic Media using Quantum Chemical Calculation and Molecular Dynamic Simulation Methods. Portugaliae Electrochimica Acta, 38(6), 377-386.
10. Umar, B. A., Uzairu, A., and Shallangwa, G. A. (2020). Quantum Modeling and Molecular Dynamic Simulation of some Amino Acids and Related Compounds on their Corrosion Inhibition of Steel in Acidic Media. Portugaliae Electrochimica Acta, 38(5), 313-329.
11. Umar, A. B., Uzairu, A., Shallangwa, G. A., and Uba, S. (2021). Ligand-based drug design and molecular docking simulation studies of some novel anticancer compounds on MALME-3M melanoma cell line. Egyptian Journal of Medical Human Genetics, 22(1), 1-15.
12. Bello, A., Uzairu, A., and Shallangwa, G. A. (2019) . Understanding Inhibition of Steel Corrosion by Some Potent Triazole Derivatives of Pyrimidine through Density Functional Theory and Molecular Dynamics Simulation Studies. Journal of the Turkish Chemical Society Section A:Chemistry, 6(3), 451-462.
13. Umar, B. A., Uzairu, A., Shallangwa, G. A., and Sani, U. (2019). QSAR modeling for the prediction of pGI50 activity of compounds on LOX IMVI cell line and ligand-based design of potent compounds using in silico virtual screening. Network Modeling Analysis in Health Informatics and Bioinformatics, 8(1), 22.
14. Umar, A. B., Uzairu, A., Shallangwa, G. A., and Uba, S. (2020). Computational evaluation of potent 2-(1H-imidazol-2-yl) pyridine derivatives as potential V600E-BRAF inhibitors. Egyptian Journal of Medical Human Genetics, 21(1), 1-11.
15. Umar, A. B., Uzairu, A., Shallangwa, G. A., and Uba, S. (2020). Design of potential antimelanoma agents against SK-MEL-5 cell line using QSAR modeling and molecular docking methods. SN Applied Sciences, 2(5), 1-18.
16. Umar, A. B., Uzairu, A., Shallangwa, G. A., and Uba, S. (2020). Docking-based strategy to design novel flavone-based arylamides as potent V600E-BRAF inhibitors with prediction of their druglikeness and ADMET properties. Bulletin of the National Research Centre, 44(1), 1-11.
17. Umar, A. B., Uzairu, A., Shallangwa, G. A., and Uba, S. (2020). In silico evaluation of some 4-(quinolin-2-yl) pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions. Future Journal of Pharmaceutical Sciences, 6(1), 1-10.
18. Umar, A. B., Uzairu, A., Shallangwa, G. A., and Uba, S. (2020). Molecular Docking Strategy to Design Novel V600E-BRAF Kinase Inhibitors with Prediction of Their Drug-Likeness and Pharmacokinetics ADMET Properties. Chemistry Africa, 1-17.
19. Umar, A. B., Uzairu, A., Shallangwa, G. A., and Uba, S. (2020). QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2. Heliyon, 6(3), e03640.
20. Umar, A. B., Uzairu, A., Uba, S., and Shallangwa, G. A. (2020). QSAR and Docking Studies on Some Potential Anti-Cancer Agents to Predict their Effect on M14 Melanoma Cell Line. Chemistry Africa, 3(4), 1009-1022.
21. Umar, A. B., Uzairu, A., Shallangwa, G. A., and Uba, S. (2021). In silico Studies of some potential anti-cancer agents on M19-MEL cell line. Moroccan Journal of Chemistry, 9(2), 260-273.
22. Abdullahi, S. H., Uzairu, A., Ibrahim, M. T., and Umar, A. B. (2021). Chemo-informatics activity prediction, ligand based drug design, Molecular docking and pharmacokinetics studies of some series of 4, 6-diaryl-2-pyrimidinamine derivatives as anti-cancer agents. Bulletin of the National Research Centre, 45(1), 1-22.
23. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S., and Umar, A. B. (2022a). Computational modeling, ligand-based drug design, drug-likeness and ADMET properties studies of series of chromen-2-ones analogues as anti-cancer agents. Bulletin of the National Research Centre, 46(1), 1-25.
24. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S., and Umar, A. B. (2022b). In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line. Bulletin of the National Research Centre, 46(1), 1-23.
25. Aminu, K. S., Uzairu, A., Abechi, S. E., Shallangwa, G. A., and Umar, A. B. (2022). Ligand-based drug design, molecular docking and pharmacokinetic studies of some series of 1, 4-dihydropyridines derivatives as human intestinal maltase-glucoamylase inhibitor. Chemical Data Collections, 41, 100911.
26. Aminu, K. S., Uzairu, A., Umar, A. B., and Ibrahim, M. T. (2022). Salicylic acid derivatives as potential α-glucosidase inhibitors: drug design, molecular docking and pharmacokinetic studies. Bulletin of the National Research Centre, 46(1), 1-14.
27. Abdulbasit, Y., Abdullahi, B., and Bishir, U. (2023). Experimental and Theoretical Evaluation of Corrosion Inhibition Performance of Senna Obtusifolia Leaves Extract on Mild Steel In 0.5 M HCl. Moroccan Journal of Chemistry, 11(2), 11-12 (2023) 2182-2299.
28. Abdullahi, S. H., Moin, A. T., Uzairu, A., Umar, A. B., Ibrahim, M. T., Usman, M. T., Nawal, N., Bayil, I., and Zubair, T. (2023). Molecular docking studies of some benzoxazole and benzothiazole derivatives as VEGFR-2 target inhibitors: In silico design, MD simulation, pharmacokinetics and DFT studies. Intelligent Pharmacy.
29. Abdullahi, S. H., Uzairu, A., Danazumi, A. U., Finbarrs-Bello, E., Umar, A. B., Shallangwa, G. A., and Uba, S. (2023). Computational design of quinoxaline molecules as VEGFR-2 inhibitors: QSAR modelling, pharmacokinetics, molecular docking, and dynamics simulation studies. Biocatalysis and Agricultural Biotechnology, 51, 102787.
30. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S., and Umar, A. B. (2022a). Computational modeling, ligand-based drug design, drug-likeness and ADMET properties studies of series of chromen-2-ones analogues as anti-cancer agents. Bulletin of the National Research Centre, 46(1), 1-25.
31. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S., and Umar, A. B. (2022b). In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line. Bulletin of the National Research Centre, 46(1), 1-23.
32. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S., and Umar, A. B. (2022c). Molecular Docking, ADMET and Pharmacokinetic properties predictions of some di-aryl Pyridinamine derivatives as Estrogen Receptor (Er+) Kinase Inhibitors. Egyptian Journal of Basic and Applied Sciences, 9(1), 180-204.
33. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S., and Umar, A. B. (2022d). Structure based design of some novel 3-methylquinoxaline derivatives through molecular docking and pharmacokinetics studies as novel VEGFR-2 inhibitors. Chemistry Africa, 5(6), 1967-1978.
34. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S., and Umar, A. B. (2023a). 2D and 3DQSAR Modeling of 1H‑Pyrazole Derivatives as EGFR Inhibitors: Molecular Docking, and Pharmacokinetic Profiling. Chemistry Africa, 1-18.
35. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S., and Umar, A. B. (2023b). Ligand-based drug design of quinazolin-4 (3H)-ones as breast cancer inhibitors using QSAR modeling, molecular docking, and pharmacological profiling. Journal of the Egyptian National Cancer Institute, 35(1), 24.
36. Abdullahi, S. H., Uzairu, A., Shallangwa, G. A., Uba, S., and Umar, A. B. (2023c). Pharmacokinetic profiling of quinazoline-4 (3H)-one analogs as EGFR inhibitors: 3D-QSAR modeling, molecular docking studies and the design of therapeutic agents. Journal of Taibah University Medical Sciences, 18(5), 1018.
37. Ajala, A., Uzairu, A., Shallangwa, G. A., Abechi, S. E., Umar, A. B., Abdulganiyyu, I. A., Ramu, R., and Kumar, N. (2023). QSAR application of natural therapeutics inhibitors against Alzheimer's disease through in-silico virtual-screening, docking-simulation, molecular dynamics, and pharmacokinetic prediction analysis. Intelligent Pharmacy.
38. Aminu, K. S., Uzairu, A., Abechi, S. E., Shallangwa, G. A., and Umar, A. B. (2024). Activity prediction, structure-based drug design, molecular docking, and pharmacokinetic studies of 1, 4- dihydropyridines derivatives as α-amylase inhibitors. Journal of Taibah University Medical Sciences, 19(2), 270-286.
39. Aminu, K. S., Uzairu, A., Umar, A., Abechi, S., and Adamu, G. (2023). A search for novel antidiabetic agents using ligand-based drug design and molecular docking studies employing human intestinal maltase-glucoamylase as model enzyme. Adv J Chem A, 6(2), 155-171.
40. Aminu, K. S., Uzairu, A., Umar, A. B., and Ibrahim, M. T. (2022). Salicylic acid derivatives as potential α-glucosidase inhibitors: drug design, molecular docking and pharmacokinetic studies. Bulletin of the National Research Centre, 46(1), 1-14.
41. Dalhatu, S. N., Modu, K. A., Mahmoud, A. A., Zango, Z. U., Umar, A. B., Usman, F., Dennis, J. O., Alsadig, A., Ibnaouf, K. H., and Aldaghri, O. A. (2023). L-Arginine grafted chitosan as corrosion inhibitor for mild steel protection. Polymers, 15(2), 398.
42. Ibrahim, M. M., Uzairu, A., Ibrahim, M. T., and Umar, A. B. (2023). Modelling PIP4K2A inhibitory activity of 1, 7-naphthyridine analogues using machine learning and molecular docking studies. RSC Advances, 13(6), 3402-3415.
43. Jibrin, A., Uzairu, A., Shallangwa, G. A., Abechi, S. E., and Umar, A. B. (2023). In-silico profiling, design, molecular docking computation, and drug kinetic model evaluation of novel curcumin derivatives as potential anticancer agents. Journal of the Indian Chemical Society, 100(4), 100979.
44. Magit, N. D., Umar, A. B., and Magit, N. D. (2023). In-silico Investigation by Molecular Docking, DFT and Pharmacokinetic Studies of Some Synthesized 1, 8-Naphthyridine Derivatives as Prospective Anti-Breast Cancer Agents. FUW Trends in Science & Technology Journal, 8 (3) 106 – 116.
45. Nulamuga, B., Uzairu, A., Babalola, I. T., Ibrahim, M. T., and Umar, A. B. (2023). In silico analysis of noscapine compounds as anti-tumor agents targeting the tubulin receptor. Journal of Taibah University Medical Sciences, 18(1), 32.
46. Umar, A. B., and Uzairu, A. (2023). Molecular modeling strategy to design novel anticancer agents against UACC-62 and UACC-257 melanoma cell lines. Egyptian Journal of Basic and Applied Sciences, 10(1), 157-173.
47. Umar, A. B., and Uzairu, A. (2023a). New flavone-based arylamides as potential V600E-BRAF inhibitors: Molecular docking, DFT, and pharmacokinetic properties. Journal of Taibah University Medical Sciences, 18(5), 1000.
48. Umar, A. B., and Uzairu, A. (2023b). Virtual screening, pharmacokinetic, and DFT studies of anticancer compounds as potential V600E-BRAF kinaseinhibitors. Journal of Taibah University Medical Sciences, 18(5), 933.
49. Umar, A. B., Uzairu, A., Ibrahim, M. T., Usman, A., Habib, A., and Usman, B. (2023). Investigation of Novel Imidazole Analogues with Terminal Sulphonamides as Potential V600EBRAF Inhibitors Through Computational Approaches. Chemistry Africa, 1-12.
